6 studies found for:    CNTO1959
Show Display Options
Rank Status Study
1 Completed A Study to Evaluate CNTO 1959 in the Treatment of Patients With Moderate to Severe Plaque-type Psoriasis
Condition: Psoriasis
Interventions: Drug: CNTO 1959 (5 mg);   Drug: CNTO 1959 (15 mg);   Drug: CNTO 1959 (50 mg);   Drug: CNTO 1959 (100 mg);   Drug: CNTO 1959 (200 mg);   Drug: Adalimumab;   Drug: Placebo
2 Completed A Study of the Safety, Tolerability, Pharmacokinetics (What the Body Does to the Drug), and Pharmacodynamics (What the Drug Does to the Body) of CNTO 1959 Following a Single Subcutaneous (Under the Skin) Administration in Japanese Participants With Moderate to Severe Plaque Psoriasis
Condition: Psoriasis
Interventions: Drug: CNTO 1959;   Drug: Placebo
3 Recruiting A Study of the Efficacy, Safety and Tolerability of CNTO 1959, a Human Anti-IL 23 Monoclonal Antibody in Participants With Palmoplantar Pustulosis
Condition: Palmoplantaris Pustulosis
Interventions: Drug: Placebo;   Drug: CNTO 1959
4 Active, not recruiting A Study of the Effectiveness and Safety of Ustekinumab (STELARA) and CNTO 1959 Administered Under the Skin of Patients With Active Rheumatoid Arthritis, Despite Existing Methotrexate Therapy
Condition: Arthritis, Rheumatoid
Interventions: Drug: Placebo + methotrexate (MTX) (Group 1);   Drug: Ustekinumab + MTX (Group 2);   Drug: Ustekinumab + MTX (Group 3);   Drug: CNTO 1959 + MTX (Group 4);   Drug: CNTO 1959 + MTX (Group 5)
5 Completed A Study of the Safety and How the Body Affects a Drug (CNTO 1959) in Healthy Volunteers and in Patients With Psoriasis
Condition: Psoriasis
Intervention: Drug: CNTO 1959; Placebo
6 Completed A Study to Assess the Pharmacokinetic Comparability of Guselkumab (CNTO1959) When Delivered by 2 Different Devices and as 2 Formulations in Healthy Participants
Condition: Healthy
Interventions: Drug: Guselkumab (lyophilized formulation);   Drug: Guselkumab (liquid formulation with PFS-U);   Drug: Guselkumab (liquid formulation with PFS FID);   Drug: Guselkumab (liquid formulation)

Indicates status has not been verified in more than two years